AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug

seekingalpha04-18

AbbVie’s (NYSE:ABBV) buyout target, Cerevel Therapeutics (NASDAQ:CERE), announced Thursday that its oral, once-daily Parkinson’s disease candidate, tavapadon, reached its main goals in a pivotal Phase...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428564865?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1143122009/image_1143122009.jpg","is_english":true,"pubTime":"2024-04-18 19:00","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2428564865","market":"fut","top_or_hot":-1,"title":"AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug","media":"seekingalpha","content":"<div>\n<p>AbbVie’s (NYSE:ABBV) buyout target, Cerevel Therapeutics (NASDAQ:CERE), announced Thursday that its oral, once-daily Parkinson’s disease candidate, tavapadon, reached its main goals in a pivotal Phase...</p>\n\n<a href=\"https://seekingalpha.com/news/4090847-abbvie-buyout-cerevel-marks-trial-win-parkinsons-disease-drug\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4090847-abbvie-buyout-cerevel-marks-trial-win-parkinsons-disease-drug><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie’s (NYSE:ABBV) buyout target, Cerevel Therapeutics (NASDAQ:CERE), announced Thursday that its oral, once-daily Parkinson’s disease candidate, tavapadon, reached its main goals in a pivotal Phase...</p>\n\n<a href=\"https://seekingalpha.com/news/4090847-abbvie-buyout-cerevel-marks-trial-win-parkinsons-disease-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0029864427.USD","symbol_name":"TEMPLETON GLOBAL \"A\" (USD) INC","start_time":0,"source_url":"https://seekingalpha.com/news/4090847-abbvie-buyout-cerevel-marks-trial-win-parkinsons-disease-drug","article_id":"2428564865","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1143122009/image_1143122009.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428564865","pubTimestamp":1713438023,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"AbbVie’s (NYSE:ABBV) buyout target, Cerevel Therapeutics (NASDAQ:CERE), announced Thursday that its oral, once-daily Parkinson’s disease candidate, tavapadon, reached its main goals in a pivotal Phase","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4581":"高盛持仓","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0237698245.USD":"富达环球地产基金A","BK4532":"文艺复兴科技持仓","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","CERE":"Cerevel Therapeutics Holdings, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4139":"生物科技","BK4534":"瑞士信贷持仓","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BMY":"施贵宝","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4588":"碎股","LU0122379950.USD":"贝莱德世界健康科学A2","ABBV":"艾伯维公司","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","RVPH":"Reviva Pharmaceuticals Holdings, Inc.","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"艾伯维收购Cerevel发布帕金森病药物后期胜利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVPH":1,"ABBV":1,"BMY":1,"CERE":1},"content_text":"AbbVie’s (NYSE:ABBV) buyout target, Cerevel Therapeutics (NASDAQ:CERE), announced Thursday that its oral, once-daily Parkinson’s disease candidate, tavapadon, reached its main goals in a pivotal Phase 3 trial as a combination therapy. The TEMPO-3 study for adults with advanced PD succeeded as tavapadon in combination with brain therapy levodopa indicated a clinically meaningful and statistically significant difference compared to placebo plus levodopa in terms of the primary endpoint, the company said. The 27-week study for 507 patients considered the change from baseline in the total “on” time without troublesome dyskinesia as the primary endpoint, which showed an increase of 1.1 hours in the on-drug arm compared to the placebo arm (1.7 hours vs. 0.6 hours). There was a statistically significant reduction in “off” time, the key secondary endpoint in the tavapadon plus levodopa arm, compared to the placebo group. Regarding safety, the company added that the study drug was well-tolerated, with most of the adverse events being mild to moderate in severity. Cerevel (CERE) expects to use the findings to support future regulatory submissions for tavapadon. Topline data from two late-stage monotherapy trials for the candidate in PD are expected in H2 2024. In December, AbbVie (ABBV) agreed to acquire Cerevel (CERE) for $8.7B. With CERE being a leading schizophrenia drug developer, its rivals Reviva Pharmaceuticals (RVPH) and Karuna Therapeutics, which Bristol Myers (BMY) acquired in March, rose in reaction. ABBV’s all-cash deal is expected to close in mid-2024.  More on AbbVie  AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals CVS favors Humira copycats hurting AbbVie’s market share: Evercore AbbVie to develop long-acting injectables in a deal worth up to $1.9B","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428564865"}